Accelerate to discover
Related topics
A mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection
Jun 3, 2020
Soft tissue sarcomas pose a significant clinical challenge, with approximately 12,000 new diagnoses and an estimated...
Saphyr identifies all variants detected by the standard of care in cytogenetics
Jun 1, 2020
Cancer genomics consortium members demonstrate 100% concordance between Bionano Genomics optical mapping technology and...
Immunophenotyping Extracellular Vesicles using Amnis CellStream
May 29, 2020
Attempts to analyze EVs using traditional PMT- based flow cytometers has been hampered by the limit of detection of...
Four-week individual caging of male ICR mice alters body composition without change in body mass
May 25, 2020
Could individual caging affect the physical composition of outbred mice? To investigate this, dual X-ray absorptiometry...
Detect structural variants at 1% allele fraction: Dive deeper into heterogeneous cancer samples
May 22, 2020
To get a complete picture of highly rearranged cancer genomes in heterogeneous samples, use Bionano genome imaging...
The qNano Gold: Obtain the most detailed Information for each individual nanoparticle
May 20, 2020
The qNano Gold measures particles using the Tunable Resistive Pulse Sensing (TRPS) principle. TRPS is the most powerful...
Insulin receptor substrate 1 is a substrate of the Pim protein kinases
May 18, 2020
The goal of these studies was to identify Pim substrate(s) that could help define the pathway regulated by these...
Webinar recording: Isolating ultra-high molecular weight (UHMW) DNA for genome analysis
May 12, 2020
Watch the webinar from Bionano Genomics and learn the tips and tricks for isolating high quality UHMW DNA - right from...
Aug 7, 2018
LSD1 is a flavin adenine dinucleotide (FAD)-dependent homolog of the amine oxidase family and there was recently brought attention to it as a potential therapeutic target. The interest came from an observation of unusually high expression of LSD1 in certain types of poor-prognosis cancers. It was previously thought that LSD1 removes monomethyl and dymethyl histone marks. However, recently it was showed that it interacts with multiple transcripton factor. This raised a possibility of other drugs being used.
New inhibitor ORY-1001 was succesfully tested on LSD1 and blast cell differentioation was observed. The flow cytometric testing on this experiment was done with Novocyte. ORY-1001 disrupts the protein interaction between LSD1 and GFI1.
Related technologies: Conventional flow cytometry
Get more info
Brand profile
ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
